Clinical and immunological features in ACKR1/DARC-associated neutropenia.

"Conflict-of-interest disclosure: J.P. is a consultant to Chiesi Canada, Ltd. E.S. is a consultant to Fate Therapeutics. S.M. is a consultant to XNK Therapeutics AB. All relationships have been reviewed and managed by Karolinska Institute, in accordance with its conflict-of-interest policies. The remaining authors declare no competing financial interests."

"This study was supported by grants to P.H. from the 10.13039/501100002794Swedish Cancer Society (2015/727; 4-331/2019; and 4-640/2022), 10.13039/501100007232Radiumhemmets Forskningsfonder (2019-2021 and 2022-2024), the 10.13039/501100003514Stockholm City Council (FoUI-952144 and FoUI-955130), 10.13039/501100018713CIMED (FoUI-955282) and Karolinska Institutet Strategic Research Area Stem Cells and Regenerative Medicine, and the work of E.S. was supported by grants to Karl-Johan Malmberg laboratory from the 10.13039/501100004359Swedish Research Council, the Swedish Cancer Society, and the Karolinska Institutet."